Literature DB >> 23756092

Clinical significance of survivin and VEGF mRNA detection in the cell fraction of the peripheral blood in non-small cell lung cancer patients before and after surgery.

X-P Tang1, J Li, L-C Yu, Y-C Chen, S-B Shi, L-R Zhu, P Chen.   

Abstract

PURPOSE: The aim of this study was to evaluate the predictive and prognostic value of peripheral blood survivin and VEGF mRNA expression levels in non-small cell lung cancer (NSCLC) patients. PATIENTS AND METHODS: Fifty-eight patients with stage I-IIIA NSCLC who underwent surgical resection were enrolled in this study. Thirty-six patients with benign lung disease (BLD) entered this study as control group. Quantitative real-time PCR was used to detect survivin and VEGF mRNA levels in the cell fraction of peripheral blood in NSCLC patients before and after surgery and BLD patients. The relationship between blood survivin and VEGF mRNA levels and patients clinicopathologic parameters and prognostic factors were investigated.
RESULTS: The levels of survivin and VEGF mRNA were decreased significantly after surgery in NSCLC patients (P = 0.024 and P = 0.012 respectively). Tumor recurrence was significantly more frequent in NSCLC patients with survivin and VEGF mRNA positivity postoperation than in patients without (P = 0.003 and P = 0.006, respectively). Patients with survivin or VEGF mRNA positivity postoperation had markedly shorter disease-free survival (DFS) and overall survival (OS) than patients without (P = 0.023 and P = 0.016 for survivin; P = 0.031 and P = 0.025 for VEGF, respectively). Multivariate analysis showed that survivin positivity preoperation (P = 0.026, P = 0.041, respectively) and postoperation (P = 0.003, P = 0.005, respectively) and VEGF mRNA positivity postoperation (P = 0.007, P = 0.009, respectively) were independently associated with DFS and OS.
CONCLUSION: Although the levels of surviving and VEGF mRNA were decreased significantly after surgery, postoperative detections of survivin and VEGF mRNA by quantitative real-time PCR could be used as tools to monitor tumor recurrence and predict prognosis.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Non-small cell lung cancer; Prognosis; Quantitative real-time PCR; Survivin; VEGF

Mesh:

Substances:

Year:  2013        PMID: 23756092     DOI: 10.1016/j.lungcan.2013.05.005

Source DB:  PubMed          Journal:  Lung Cancer        ISSN: 0169-5002            Impact factor:   5.705


  11 in total

1.  Survivin mRNA expression in blood as a predictor of the response to EGFR-tyrosine kinase inhibitors and prognosis in patients with non-small cell lung cancer.

Authors:  Wei-Lin Shi; Jian Li; Quan-Lei Bao; Jian-Nong Wu; Li-Ping Ge; Li-Rong Zhu; Yi Wang; Wen-Fang Zhu
Journal:  Med Oncol       Date:  2014-02-23       Impact factor: 3.064

2.  Survivin mRNA Level in Blood Predict the Efficacy of Neoadjuvant Chemotherapy in Patients with Stage IIIA-N2 Non-Small Cell Lung Cancer.

Authors:  Yi-Ming Hu; Jing Li; Li-Chao Yu; Shun-Bing Shi; Yong-Jie Du; Jian-Nong Wu; Wei Lin Shi
Journal:  Pathol Oncol Res       Date:  2014-07-01       Impact factor: 3.201

3.  Predicting ovarian cancer recurrence by plasma metabolic profiles before and after surgery.

Authors:  Fan Zhang; Yuanyuan Zhang; Chaofu Ke; Ang Li; Wenjie Wang; Kai Yang; Huijuan Liu; Hongyu Xie; Kui Deng; Weiwei Zhao; Chunyan Yang; Ge Lou; Yan Hou; Kang Li
Journal:  Metabolomics       Date:  2018-04-26       Impact factor: 4.290

4.  Survivin mRNA-circulating tumor cells predict treatment efficacy of chemotherapy and survival for advanced non-small cell lung cancer patients.

Authors:  Yong-Jie Du; Jian Li; Wen-Fang Zhu; Yan Wu; Xin-Ping Tang; Yi Wang; Yi-Ming Hu
Journal:  Tumour Biol       Date:  2014-01-05

5.  Survivin mRNA-circulating tumor cells are associated with prostate cancer metastasis.

Authors:  Huansheng Wang; Mingshan Yang; Jian Xu; Benkui Zou; Qian Zhou; Jiasheng Bian; Xingwu Wang
Journal:  Tumour Biol       Date:  2015-08-06

6.  Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer.

Authors:  Jian Li; Yi-Ming Hu; Yong-Jie Du; Li-Rong Zhu; Hai Qian; Yan Wu; Wei-Lin Shi
Journal:  BMC Cancer       Date:  2014-11-19       Impact factor: 4.430

7.  SIRT1 expression is associated with poor prognosis of lung adenocarcinoma.

Authors:  Chong Li; Lingling Wang; Liang Zheng; Xianghong Zhan; Bin Xu; Jingting Jiang; Changping Wu
Journal:  Onco Targets Ther       Date:  2015-04-30       Impact factor: 4.147

8.  RNA interferences targeting the Fanconi anemia/BRCA pathway upstream genes reverse cisplatin resistance in drug-resistant lung cancer cells.

Authors:  Chun-Hua Dai; Jian Li; Ping Chen; He-Guo Jiang; Ming Wu; Yong-Chang Chen
Journal:  J Biomed Sci       Date:  2015-09-18       Impact factor: 8.410

9.  Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.

Authors:  Liang Duan; Xuefei Hu; Yuxing Jin; Ruijun Liu; Qingjun You
Journal:  BMC Cancer       Date:  2016-04-18       Impact factor: 4.430

10.  Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.

Authors:  Rita Puskas; Andras Bikov; Peter Horvath; Zsofia Lazar; Laszlo Kunos; Reka Nagy; Gabriella Pinter; Gabriella Galffy
Journal:  Pathol Oncol Res       Date:  2021-04-30       Impact factor: 3.201

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.